Critical Path follow-on biologics projects idle
Executive Summary
FDA Chief Medical Officer Janet Woodcock says there is little interest by industry in follow-on biologics projects under the Critical Path Initiative. "I don't think that we've gotten a lot of partners to work on those different projects, they are not very prominent," she observes. The agency's opportunities list includes two projects - Novel Approaches to Characterizing and Standardizing Biological Products and Enabling Manufacturing Changes for Well-Characterized Proteins - that could clarify underlying scientific issues complicating development of regulatory policy on follow-on biologics (1"The Pink Sheet" April 10, 2006, p. 13)...
You may also be interested in...
FDA Sees Critical Path Opportunity To Address Follow-On Biologics
FDA's Critical Path opportunities list suggests that the agency is actively working to lay the scientific groundwork for follow-on biologics
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.